company background image
UCB logo

UCB ENXTBR:UCB Stock Report

Last Price

€127.60

Market Cap

€24.2b

7D

4.1%

1Y

51.3%

Updated

22 May, 2024

Data

Company Financials +

UCB Stock Overview

A biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide.

UCB fundamental analysis
Snowflake Score
Valuation2/6
Future Growth4/6
Past Performance1/6
Financial Health4/6
Dividends0/6

Rewards

Risk Analysis

No risks detected for UCB from our risk checks.

UCB SA Competitors

Price History & Performance

Summary of all time highs, changes and price drops for UCB
Historical stock prices
Current Share Price€127.60
52 Week High€129.15
52 Week Low€65.40
Beta0.38
1 Month Change4.59%
3 Month Change33.53%
1 Year Change51.26%
3 Year Change66.06%
5 Year Change86.33%
Change since IPO41,717.42%

Recent News & Updates

Shareholders Will Probably Not Have Any Issues With UCB SA's (EBR:UCB) CEO Compensation

Apr 19
Shareholders Will Probably Not Have Any Issues With UCB SA's (EBR:UCB) CEO Compensation

Recent updates

Shareholders Will Probably Not Have Any Issues With UCB SA's (EBR:UCB) CEO Compensation

Apr 19
Shareholders Will Probably Not Have Any Issues With UCB SA's (EBR:UCB) CEO Compensation

Is UCB (EBR:UCB) A Risky Investment?

Mar 27
Is UCB (EBR:UCB) A Risky Investment?

Earnings Tell The Story For UCB SA (EBR:UCB) As Its Stock Soars 26%

Mar 04
Earnings Tell The Story For UCB SA (EBR:UCB) As Its Stock Soars 26%

UCB SA's (EBR:UCB) P/E Is On The Mark

Dec 28
UCB SA's (EBR:UCB) P/E Is On The Mark

UCB (EBR:UCB) Takes On Some Risk With Its Use Of Debt

Nov 12
UCB (EBR:UCB) Takes On Some Risk With Its Use Of Debt

Is UCB (EBR:UCB) Using Too Much Debt?

Aug 07
Is UCB (EBR:UCB) Using Too Much Debt?

Are Investors Undervaluing UCB SA (EBR:UCB) By 48%?

Jun 02
Are Investors Undervaluing UCB SA (EBR:UCB) By 48%?

UCB's (EBR:UCB) Upcoming Dividend Will Be Larger Than Last Year's

Apr 05
UCB's (EBR:UCB) Upcoming Dividend Will Be Larger Than Last Year's

Does UCB (EBR:UCB) Have A Healthy Balance Sheet?

Apr 03
Does UCB (EBR:UCB) Have A Healthy Balance Sheet?

Here's Why UCB (EBR:UCB) Can Manage Its Debt Responsibly

Dec 05
Here's Why UCB (EBR:UCB) Can Manage Its Debt Responsibly

These 4 Measures Indicate That UCB (EBR:UCB) Is Using Debt Reasonably Well

Sep 05
These 4 Measures Indicate That UCB (EBR:UCB) Is Using Debt Reasonably Well

Does UCB (EBR:UCB) Have A Healthy Balance Sheet?

Jun 06
Does UCB (EBR:UCB) Have A Healthy Balance Sheet?

UCB (EBR:UCB) Is Paying Out A Larger Dividend Than Last Year

Apr 23
UCB (EBR:UCB) Is Paying Out A Larger Dividend Than Last Year

UCB's (EBR:UCB) Upcoming Dividend Will Be Larger Than Last Year's

Apr 09
UCB's (EBR:UCB) Upcoming Dividend Will Be Larger Than Last Year's

UCB (EBR:UCB) Has Announced That It Will Be Increasing Its Dividend To €0.91

Mar 26
UCB (EBR:UCB) Has Announced That It Will Be Increasing Its Dividend To €0.91

Here's Why UCB (EBR:UCB) Can Manage Its Debt Responsibly

Dec 23
Here's Why UCB (EBR:UCB) Can Manage Its Debt Responsibly

Are Investors Undervaluing UCB SA (EBR:UCB) By 42%?

Dec 05
Are Investors Undervaluing UCB SA (EBR:UCB) By 42%?

Here's Why UCB (EBR:UCB) Can Manage Its Debt Responsibly

Sep 23
Here's Why UCB (EBR:UCB) Can Manage Its Debt Responsibly

UCB SA (EBR:UCB) Shares Could Be 44% Below Their Intrinsic Value Estimate

Sep 05
UCB SA (EBR:UCB) Shares Could Be 44% Below Their Intrinsic Value Estimate

UCB SA Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Jul 31
UCB SA Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Is UCB (EBR:UCB) A Risky Investment?

Jun 21
Is UCB (EBR:UCB) A Risky Investment?

UCB SA's (EBR:UCB) Intrinsic Value Is Potentially 96% Above Its Share Price

May 13
UCB SA's (EBR:UCB) Intrinsic Value Is Potentially 96% Above Its Share Price

Is UCB (EBR:UCB) Using Too Much Debt?

Mar 18
Is UCB (EBR:UCB) Using Too Much Debt?

Will Weakness in UCB SA's (EBR:UCB) Stock Prove Temporary Given Strong Fundamentals?

Feb 28
Will Weakness in UCB SA's (EBR:UCB) Stock Prove Temporary Given Strong Fundamentals?

UCB SA's (EBR:UCB) Intrinsic Value Is Potentially 54% Above Its Share Price

Feb 10
UCB SA's (EBR:UCB) Intrinsic Value Is Potentially 54% Above Its Share Price

What Makes UCB SA (EBR:UCB) A Great Dividend Stock?

Jan 20
What Makes UCB SA (EBR:UCB) A Great Dividend Stock?

Is UCB SA (EBR:UCB) Popular Amongst Institutions?

Jan 07
Is UCB SA (EBR:UCB) Popular Amongst Institutions?

UCB (EBR:UCB) Is Growing Earnings But Are They A Good Guide?

Dec 23
UCB (EBR:UCB) Is Growing Earnings But Are They A Good Guide?

Shareholder Returns

UCBBE PharmaceuticalsBE Market
7D4.1%0.6%-1.0%
1Y51.3%13.5%5.3%

Return vs Industry: UCB exceeded the Belgian Pharmaceuticals industry which returned 12.7% over the past year.

Return vs Market: UCB exceeded the Belgian Market which returned 4.1% over the past year.

Price Volatility

Is UCB's price volatile compared to industry and market?
UCB volatility
UCB Average Weekly Movement3.9%
Pharmaceuticals Industry Average Movement5.0%
Market Average Movement3.8%
10% most volatile stocks in BE Market7.9%
10% least volatile stocks in BE Market2.5%

Stable Share Price: UCB's share price has been volatile over the past 3 months.

Volatility Over Time: UCB's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19258,767Jean-Christophe Tellierwww.ucb.com

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company’s primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson’s disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome.

UCB SA Fundamentals Summary

How do UCB's earnings and revenue compare to its market cap?
UCB fundamental statistics
Market cap€24.21b
Earnings (TTM)€343.00m
Revenue (TTM)€5.18b

70.6x

P/E Ratio

4.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
UCB income statement (TTM)
Revenue€5.18b
Cost of Revenue€1.71b
Gross Profit€3.48b
Other Expenses€3.13b
Earnings€343.00m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

Jul 25, 2024

Earnings per share (EPS)1.81
Gross Margin67.06%
Net Profit Margin6.62%
Debt/Equity Ratio32.1%

How did UCB perform over the long term?

See historical performance and comparison

Dividends

1.1%

Current Dividend Yield

75%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.